 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| VX-864 / Vertex
Trial completion, Enrollment change, Trial completion date: A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype (clinicaltrials.gov) - Sep 20, 2024
P2, N=14, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed | N=20 --> 14 | Trial completion date: Dec 2024 --> Aug 2024
- | VX-864 / Vertex
Enrollment closed: A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype (clinicaltrials.gov) - Oct 26, 2023
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed | N=20 --> 14 | Trial completion date: Dec 2024 --> Aug 2024 Recruiting --> Active, not recruiting
- || VX-864 / Vertex
Enrollment open: A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype (clinicaltrials.gov) - Dec 23, 2022
P2, N=20, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || VX-864 / Vertex
New P2 trial: A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype (clinicaltrials.gov) - Dec 8, 2022
P2, N=20, Not yet recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- || VX-864 / Vertex
Trial completion: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype (clinicaltrials.gov) - Jun 16, 2021
P2, N=44, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | VX-864 / Vertex
VX-864 will *not* advance into late-stage development (Twitter) - Jun 10, 2021
- | VX-864 / Vertex
Enrollment closed: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype (clinicaltrials.gov) - Feb 21, 2021
P2, N=40, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || VX-864 / Vertex
Enrollment open: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype (clinicaltrials.gov) - Jul 20, 2020
P2, N=40, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || VX-864 / Vertex
New P2 trial: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype (clinicaltrials.gov) - Jul 16, 2020
P2, N=40, Not yet recruiting, Sponsor: Vertex Pharmaceuticals Incorporated